ライフサイエンスコーパス: malignant neoplasm

1 ounger than 18 years or who had an abdominal malignant neoplasm.

2 and contributes to STAT3 activation in this malignant neoplasm.

3 for the diagnosis and staging of this highly malignant neoplasm.

4 te cause of death could be attributed to the malignant neoplasm.

5 Seventy-two patients have developed a second malignant neoplasm.

6 : SOTRs and patients with HIV or hematologic malignant neoplasm.

7 ive RPF or malignant RPF and retroperitoneal malignant neoplasm.

8 No patient developed tuberculosis or a malignant neoplasm.

9 e MMP but not preferentially in those with a malignant neoplasm.

10 at this phosphorylation event might identify malignant neoplasms.

11 s diseases, such as autoimmune disorders and malignant neoplasms.

12 carcinomas (BCCs), are the most common human malignant neoplasms.

13 icity, hearing loss, infertility, and second malignant neoplasms.

14 , 77 (13.5%) benign neoplasms, and 18 (3.2%) malignant neoplasms.

15 Two had second malignant neoplasms.

16 ep in the in the proliferation and spread of malignant neoplasms.

17 protein family that is expressed in several malignant neoplasms.

18 in a variety of disease processes, including malignant neoplasms.

19 creased susceptibility to the development of malignant neoplasms.

20 hway and is inactivated in a wide variety of malignant neoplasms.

21 ed cardiac function, infertility, and second malignant neoplasms.

22 ents with a variety of primary and secondary malignant neoplasms.

23 hyperplasia, and a predisposition to develop malignant neoplasms.

24 eptor staining in the majority (15 of 19) of malignant neoplasms.

25 sociated neovasculature of a wide variety of malignant neoplasms.

26 bromas, renal tumours and uterine benign and malignant neoplasms.

27 Resected livers were evaluated for malignant neoplasms.

28 romising new strategies for the treatment of malignant neoplasms.

29 dgkin's disease is the development of second malignant neoplasms.

30 IGF-1 also facilitate growth of a number of malignant neoplasms.

31 ere diagnosed in 54 individuals as benign or malignant neoplasms.

32 ion approvals for patients with a variety of malignant neoplasms.

33 n increased risk of posttransplant cutaneous malignant neoplasms.

34 ell depletion are risk factors for cutaneous malignant neoplasms.

35 reased risk for treatment-related subsequent malignant neoplasms.

36 known to distinguish borderline from overtly malignant neoplasms.

37 ive prognostic factor for a diverse range of malignant neoplasms.

38 tion by PET in patients with newly diagnosed malignant neoplasms.

39 s and seems to be associated with concurrent malignant neoplasms.

40 thrombocytopenic patients with hematological malignant neoplasms?

41 erebrovascular disease 0.88 [0.81-0.95], all malignant neoplasms 0.92 [0.88-0.95], and respiratory di

42 l burden in people aged 60 years and older), malignant neoplasms (15.1%), chronic respiratory disease

43 rt (268.5), cerebrovascular disease (242.3), malignant neoplasms (214.1), pneumonia and influenza (45

44 : overall 95.5; death due to HL 38.3, second malignant neoplasms 23.9, and cardiovascular disease 13.

45 Cardiovascular diseases (34.7%) and malignant neoplasms (31.8%) were the leading causes of d

46 n-communicable causes 40.9%; injuries 15.1%; malignant neoplasms 5.1%; neuropsychiatric conditions 10

47 ssue in assessing the risk of second-primary malignant neoplasms, a major late effect of concern, usi

48 y tumors, metastatic disease, or hematologic malignant neoplasms admitted to medical and surgical int

49 05 of 129 patients who developed a secondary malignant neoplasm after ALL treatment on 7 consecutive

50 ay a major role in the etiology of secondary malignant neoplasm after treatment for childhood ALL, ac

51 harts of 149 patients with an extrapulmonary malignant neoplasm and a solitary pulmonary nodule.

52 range of late complications, with subsequent malignant neoplasm and cardiovascular disease representi

53 m peritoneal carcinomatosis from any primary malignant neoplasm and excluded case studies, curative s

54 ry hypothyroidism, breast cancer as a second malignant neoplasm and suggests an increased prevalence

55 ic fluid was shown in 21 of 25 patients with malignant neoplasms and 48 of 62 patients with benign di

56 le in a fraction of patients across multiple malignant neoplasms and can be reactivated by targeting

57 Secondary malignant neoplasms and cardiovascular disease represent

58 d in the neovasculature of a wide variety of malignant neoplasms and may be an effective target for m

59 ion between insulin-like growth factor-I and malignant neoplasms and quality-of-life issues with long

60 ms or signs of VLS, scarring, development of malignant neoplasms, and adverse effects.

61 ts of treatment, such as infertility, second malignant neoplasms, and cardiopulmonary injury.

62 data for the subset who developed cutaneous malignant neoplasms, and cutaneous malignant neoplasm ri

63 owth controller, is highly activated in some malignant neoplasms, and its clinical implications are u

64 atients had benign cysts; eight, borderline (malignant) neoplasms; and three, carcinoma in situ lesio

65 Second malignant neoplasms are a major cause of late morbidity

66 Second malignant neoplasms are a serious complication after suc

67 Malignant neoplasms are consistently among the top four

68 inogenesis in this model, we report that all malignant neoplasms arise from the proximal region of th

69 us cell carcinoma (HNSCC) is the most common malignant neoplasm arising in the mucosa of the upper ae

70 ion, and exhibited progression to aggressive malignant neoplasms, as is often observed in human carci

71 with a high incidence of medulloblastoma, a malignant neoplasm believed to arise from immature precu

72 patients age 20 to 40 years diagnosed with a malignant neoplasm between 2007 and 2009.

73 pecially in SOTRs and those with hematologic malignant neoplasm, but not patients with HIV.

74 Autopsy often reveals new diagnoses of malignant neoplasms, but as technological advances to im

75 late-occurring complications such as second malignant neoplasms, cardiovascular disease, endocrinopa

76 enefit nor harm in terms of the incidence of malignant neoplasms, cardiovascular disease, or death fr

77 determinant in 3 (ie, diseases of the heart, malignant neoplasms, cerebrovascular diseases) of the to

78 on in hyperplastic tissues and in benign and malignant neoplasms compared with normal tissues.

79 ions in IS patients (SOTRs, HIV, hematologic malignant neoplasm) compared with IC patients.

80 ith the neovasculature of a wide spectrum of malignant neoplasms: conventional (clear cell) renal car

81 erson-years; the highest AERs were found for malignant neoplasms, diseases of digestive organs, and d

82 ors of childhood cancer may develop a second malignant neoplasm during adulthood and therefore requir

83 % CI, 1.53-2.49; P < .001), and not having a malignant neoplasm (eg, BRCA carriers) (OR, 3.13; 95% CI

84 Malignant neoplasms enhanced (median, 38.1 HU; range, 14

85 When analyzed by type of malignant neoplasm, ERCP was associated with a lower rat

86 Malignant neoplasms evolve in response to changes in onc

87 In the beta carotene group, 1273 men had any malignant neoplasm (except nonmelanoma skin cancer), as

88 Malignant neoplasms exhibit an elevated rate of glycolys

89 The standardized incidence ratio for all malignant neoplasms for all participants was 72% (95% CI

90 ients with malignant RPF and retroperitoneal malignant neoplasm; group II, 16 patients with chronic R

91 activators for targeted molecular therapy of malignant neoplasms harboring WT p53 and elevated levels

92 Subsequent malignant neoplasm history was determined in 13,136 part

93 HR, 1.7; 95% CI, 1.2-2.5), non-breast second malignant neoplasm (HR, 2.6; 95% CI 1.4-5.1), or a serio

94 , 95% confidence interval (CI): 1.03, 1.07), malignant neoplasms (HR = 1.06, 95% CI: 1.03, 1.09), lun

95 adiotherapy, and 42 (59%) developed a second malignant neoplasm in a previous radiotherapy field.

96 rcinoma (BCC) of the skin is the most common malignant neoplasm in humans.

97 benign nodal hyperplasia in 251 patients and malignant neoplasm in two patients.

98 One hundred eleven malignant neoplasms in 100 patients had been either undi

99 er (HCC) are the most common primary hepatic malignant neoplasms in childhood.

100 ars of YPLL than did either heart disease or malignant neoplasms in every year of observation.

101 Given the increased risk of cutaneous malignant neoplasms in hematopoietic cell transplant rec

102 lication and smoking, and the development of malignant neoplasms in kidney transplant recipients.

103 We interrogated RNA-Seq data from 3,775 malignant neoplasms in The Cancer Genome Atlas database

104 ce between clinical and autopsy diagnoses of malignant neoplasms in this study is 44%, which is simil

105 Malignant neoplasms, including colon cancers, are though

106 ydroxylase (AAH) is overexpressed in various malignant neoplasms, including hepatocellular carcinomas

107 e at increased risk of CUP and several other malignant neoplasms, including lung, pancreatic, and col

108 ew therapies to treat patients with advanced malignant neoplasms, including metastatic non-small cell

109 immunodeficiency virus (HIV) or hematologic malignant neoplasms, increases the risk of developing no

110 2q24 are frequently reported in a variety of malignant neoplasms, indicating the presence of a tumor

111 y-related health care utilization, including malignant neoplasm, inflammatory bowel disease, human im

112 The transformation of a healthy cell into a malignant neoplasm involves numerous genetic mutations a

113 mas represent a diverse group of hematologic malignant neoplasms involving different tissues within t

114 te between clinical and autopsy diagnoses of malignant neoplasms is large and confirms the importance

115 s, but how these benign lesions develop into malignant neoplasms is not understood.

116 the increase in incidence of more aggressive malignant neoplasms is significantly higher than expecte

117 incidence of IOS was calculated with second malignant neoplasm, late recurrence, and death as compet

118 ected (PMR=1.21, 95% CI 1.14-1.28) to have a malignant neoplasm listed on their death certificates, b

119 esota to determine the incidence of post-BMT malignant neoplasms (MNs).

120 The five leading causes of death were malignant neoplasms (mortality, 374.1 per 100,000 person

121 ed elevated when patients with pretransplant malignant neoplasms (n = 1124) were excluded (SMR, 1.93

122 and parasitic diseases (n = 62 [11.8%]), and malignant neoplasms (n = 20 [3.8%]).

123 ry nodules were studied in 107 patients with malignant neoplasms (n = 52), granulomas (n = 51), and b

124 Second malignant neoplasms occurred mainly in patients treated

125 y neoplasm (odds ratio, 2.58; P < .0001) and malignant neoplasm (odds ratio, 4.94; P = .005).

126 as also an independent prognostic factor for malignant neoplasms (odds ratio, 12.76; 95% CI, 2.43-66.

127 ma is the second most common solid pediatric malignant neoplasm of bone and soft tissue.

128 duct carcinoma (CDC) of the kidney is a rare malignant neoplasm of distal nephron origin.

129 Melanoma is a highly malignant neoplasm of melanocytes with considerable meta

130 Rhabdomyosarcoma is a malignant neoplasm of primitive mesenchyme exhibiting sk

131 Neuroblastoma (NB) is a pediatric malignant neoplasm of sympathoadrenal origin.

132 Cholangiocarcinoma is a highly malignant neoplasm of the biliary tree.

133 Cervical cancer, the malignant neoplasm of the cervix uteri is the second mos

134 clear cell renal carcinoma, the most common malignant neoplasm of the human kidney.

135 iary cystadenocarcinoma is a rare epithelial malignant neoplasm of the liver or extrahepatic bile duc

136 rt, we present a case of an undifferentiated malignant neoplasm of unknown origin presenting as benig

137 angioendothelioma (EH) is a rare, low-grade, malignant neoplasm of vascular origin that may develop a

138 and IL-23 participate in the development of malignant neoplasms of keratinocytes.

139 , collected data on all malignancies and non-malignant neoplasms of the CNS diagnosed before age 20 y

140 Malignant neoplasms of the hepatopancreaticobiliary (HPB

141 Malignant neoplasms of the ocular surface are uncommon b

142 Pancreatoblastomas are unusual malignant neoplasms of the pediatric pancreas that may a

143 The most common human cancers are malignant neoplasms of the skin.

144 excess subsequent all-cause, cancer (second malignant neoplasms only), and cardiac mortality rates.

145 None of the patients demonstrated second malignant neoplasm or systemic metastasis.

146 late differences in the overall incidence of malignant neoplasms or cardiovascular disease, or in ove

147 id tumors, whereas patients with hematologic malignant neoplasms or less severe illness seem to benef

148 There were no malignant neoplasms or opportunistic infections reported

149 r esophageal/laryngeal involvement; internal malignant neoplasm; or BP180 ELISA score.

150 Cholangiocarcinoma is a malignant neoplasm originating from cholangiocytes.

151 By contrast, malignant neoplasms other than leukaemia were listed on

152 ants were similarly distributed in secondary malignant neoplasm patients and the overall ALL patient

153 eases, the age-adjusted mortality due to all malignant neoplasms plateaued, then decreased by 1.0 per

154 f the same cancer occurring as first primary malignant neoplasm (PM) by age.

155 d in age at diagnosis, sex, history of other malignant neoplasm, presenting visual acuity, distance o

156 rhabdoid tumor (ATRT) of the CNS is a highly malignant neoplasm primarily affecting young children, w

157 tinal obstruction (10 [5%] of 204 patients), malignant neoplasm progression (10 [5%]), and anaemia (n

158 ten [4%]), asthenia (14 [5%] vs five [2%]), malignant neoplasm progression (18 [6%] vs 11 [4%]), inc

159 The most common serious adverse events were malignant neoplasm progression (eight of 52 [15%] with p

160 se event of any grade or grade 3 or more was malignant neoplasm progression.

161 a group of histologically diverse benign and malignant neoplasms, represent a challenging problem for

162 iferation, which is a hallmark of aggressive malignant neoplasms, requires a general increase in prot

163 s an option, proportions of any neoplasm and malignant neoplasm, respectively, were 1% and 0% in SRU

164 guidelines, proportions of any neoplasm and malignant neoplasm, respectively, were 1% and 0% in SRU

165 cutaneous malignant neoplasms, and cutaneous malignant neoplasm risk factors were extracted from incl

166 In the assessment of second-primary malignant neoplasm risk, attained age is a critical fact

167 diseases (RR, 1.69; 95% CI, 1.61-1.77), and malignant neoplasms (RR, 1.63; 95% CI, 1.59-1.68).

168 Otherwise, borderline-malignant neoplasms seemed to have a similar spectrum of

169 emale survivors at average risk for a second malignant neoplasm show reasonable rates of screening fo

170 oma (CRC) has been described as a subsequent malignant neoplasm (SMN), although little is known about

171 cer (GCC) are at increased risk for a second malignant neoplasm (SMN).

172 SC) had a cumulative incidence of subsequent malignant neoplasm (SMN; ie, malignancies excluding NMSC

173 Second malignant neoplasms (SMN) are devastating late complicat

174 Secondary malignant neoplasms (SMN) are increasingly common compli

175 Second malignant neoplasms (SMN) are therapy-induced malignanci

176 Second malignant neoplasms (SMNs) after diagnosis of childhood

177 We assessed mortality and second malignant neoplasms (SMNs) among 1082 5-year survivors o

178 cts of cancer and its treatment, with second malignant neoplasms (SMNs) comprising one of the most po

179 Despite recognition that second malignant neoplasms (SMNs) contribute significantly to m

180 azoxane and the risk of developing secondary malignant neoplasms (SMNs) in children with Hodgkin's di

181 Second malignant neoplasms (SMNs) were ascertained by medical r

182 and standardized incidence ratios for second malignant neoplasms (SMNs) were calculated.

183 s (SIRs), excess absolute risk of subsequent malignant neoplasms (SMNs), and relative risks (RRs) for

184 at risk for radiation therapy-induced second malignant neoplasms (SMNs).

185 dgkin's lymphoma (HL) are at risk for second malignant neoplasms (SMNs).

186 L)/myelodysplastic syndrome (MDS) and second malignant neoplasms (SMNs).

187 (CCSs) are at increased risk for subsequent malignant neoplasms (SMNs).

188 survivors have increased risk of subsequent malignant neoplasms (SMNs).

189 inal disease, late effects (including second malignant neoplasms [SMNs], cardiac causes, pulmonary di

190 gh the increased incidence of second primary malignant neoplasms (SPMs) is a well-known late effect a

191 Six (1%) survivors developed a subsequent malignant neoplasm (standardised incidence ratio 2.6, 95

192 arcinoma (MCC) is a cutaneous neuroendocrine malignant neoplasm that can be highly aggressive and ult

193 oma (OSCC) accounts for more than 90% of the malignant neoplasms that arise in the mucosa of the uppe

194 Ampullary carcinomas are highly malignant neoplasms that can have either intestinal or p

195 ociated with myelogenous leukemias and other malignant neoplasms, this study concludes that K12 is a

196 n clinical trials for treatment of different malignant neoplasms; trametinib dimethyl sulfoxide was a

197 Thirty-one patients with known or suspected malignant neoplasms underwent imaging with both methods,

198 ; P < .001), and the presence of hematologic malignant neoplasm was associated with 1.74 times the od

199 required follow-up and in whom a new primary malignant neoplasm was detected.

200 s aspiration biopsy samples acquired because malignant neoplasm was suspected clinically that were ob

201 nd smoking, the incidence rate ratio for all malignant neoplasms was 0.89 (95% CI: 0.80, 1.00).

202 median serum CA19-9 level for patients with malignant neoplasms was 210 vs 15 U/mL for those without

203 Risk of second malignant neoplasms was highest among patients treated w

204 Diagnostic accuracy for malignant neoplasms was highest at an MPD diameter cutof

205 A history of noncutaneous malignant neoplasms was observed in 21.3% of the patient

206 The annual YPLL attributed to malignant neoplasms was similar to that for heart diseas

207 tcomes (nonneoplastic cyst, benign neoplasm, malignant neoplasm) was compared in each rating group by

208 cy of core-needle biopsy in the detection of malignant neoplasms were 61% (11 of 18), 100% (181 of 18

209 Observed-to-expected (O/E) ratios for second malignant neoplasms were calculated with the use of age-

210 A total of 1,466 incident malignant neoplasms were diagnosed during the study peri

211 Malignant neoplasms were enhanced (median, 46.5 HU; rang

212 Second malignant neoplasms were evaluated among 32,251 women wi

213 The most common malignant neoplasms were nonmelanoma skin (n = 35), brea

214 No second malignant neoplasms were observed.

215 Pancreatic cancer is a malignant neoplasm with a high mortality rate.

216 id dendritic cell neoplasm (BPDCN) is a rare malignant neoplasm with cutaneous manifestations and a r

217 Anorectal melanoma is a rare malignant neoplasm with variable natural history and non

218 (ESFT) comprises several well-characterized malignant neoplasms with particularly aggressive behavio

219 to differential diagnosis of chronic RPF and malignant neoplasms with RPF morphology.